October 29, 2024 |
Pharma companion apps are transforming healthcare by offering support beyond traditional treatments, enhancing patient engagement and outcomes. From medication reminders to symptom tracking, these apps provide valuable tools for both patients and healthcare professionals. Explore the benefits of branded companion apps, learn about the regulatory landscape, and discover how they’re adding value across healthcare, ultimately bridging the gap between digital technology and effective patient care. Dive into this evolving landscape and see how it can reshape your healthcare strategy.

Pharma companion apps are revolutionising patient care and clinical practice, offering valuable support that goes “beyond the pill.” Much like the apps paired with tech gadgets to enhance user experience, branded pharma companion apps aim to improve medication adherence, disease management, and overall health outcomes.
Recent years have seen a surge in the adoption of digital health tools, such as mobile health apps and wearables, that allow individuals to manage their health more effectively. This trend offers pharma companies an opportunity to integrate digital solutions with their products, creating comprehensive patient support ecosystems that extend beyond the pill.
The COVID-19 pandemic accelerated the adoption of digital health technologies, with a notable increase in telehealth and remote monitoring. Countries like Germany have pioneered initiatives like DiGA, which allow prescribed digital health apps to be reimbursed by insurance, offering a potential roadmap for pharma companies looking to add digital value to their medicines. Meanwhile, the UK is still evolving in integrating digital apps into the healthcare framework, though there has been significant progress.
Pharma companion apps are designed to accompany specific prescription drugs, offering features like medication reminders, symptom tracking, educational content, and interactive tools such as dose calculators. These features aim to support patients in managing their conditions more effectively and provide healthcare professionals (HCPs) with real-time data.
The development of pharma companion apps is subject to regulatory guidelines. In the US, the FDA provides draft guidance on Prescription Drug-Use-Related Software (PDURS), categorising companion apps based on their impact on clinical outcomes. Meanwhile, UK-based pharma companies must adhere to the Digital Technology Assessment Criteria (DTAC) to ensure safety, effectiveness, data protection, and interoperability.
Pharma apps also need to comply with medical device regulations, including classification under the Medicines and Healthcare products Regulatory Agency (MHRA), ensuring UK CA marking for the UK market, and CE marking for European compliance. Not all apps are classified as medical devices, but it’s essential to evaluate each app based on its intended use and claims.
Pharma companion apps have proven effective across various medical conditions, such as diabetes management, mental health support, and cardiovascular health. These apps help patients track symptoms, adhere to treatment plans, and share data with HCPs for better management.
Future trends in medical app development include using artificial intelligence (AI) and machine learning for personalised care, integrating augmented and virtual reality for patient education, and expanding app functionalities through wearable technology integration.
Pharma companion apps present an opportunity for pharma companies to foster better patient engagement, support healthcare professionals, and deliver value beyond the pill. By embracing these digital tools and ensuring regulatory compliance, companies can enhance healthcare delivery and outcomes, ultimately transforming the patient care experience.
Read the Full Article on Genetic Digital
This content was provided by Genetic Digital
Company Details
Latest Content from Genetic Digital
Genetic Digital wins Silver at the PM Society Digital Awards for Epilepsy Meds, a clinical support app developed with Desitin and ChangeMed to aid patient-specific prescribing in epilepsy care.
Genetic Digital has been shortlisted for a PM Society Digital Award for Epilepsy Meds, a mobile-first app that helps healthcare professionals make safer, patient-specific prescribing decisions in epilepsy care. The...
Pharma marketers are embracing chat-based tools to engage HCPs and patients faster, simplify PI sharing, and gain real-time insights — all while staying ABPI and GDPR compliant. When aligned with...
In many pharma teams, the responsibility for keeping prescribing information (PI) up to date online falls into a grey area. > Regulatory signs it off. > Marketing publishes it. >...
As we approach 2025, healthcare and life sciences SMEs face an increasingly digital world. A seamless, mobile-friendly website that harnesses AI-driven personalisation and intuitive design elements isn’t just a luxury...
ABPI's recent update permits QR codes in printed pharmaceutical materials for prescribing information. By ensuring visibility, providing clear instructions, linking directly, and keeping content current, companies can enhance accessibility, ensure...
Life sciences digital agency Genetic Digital has launched Pi 360, a cutting-edge web application designed to help pharmaceutical companies automate the creation, management and distribution of Prescribing Information (PI) while...
Pharma companies must balance HCP access and MHRA/ABPI compliance by preventing public search indexing of promotional prescription medicine content.
Pharma companion apps are transforming healthcare by offering support beyond traditional treatments, enhancing patient engagement and outcomes. From medication reminders to symptom tracking, these apps provide valuable tools for both...
